Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations

Home | Back to Product Details

Additional Information about Patents

• Patent information is published on or after the submission date as defined in 21 CFR 314.53(d)(5).
• Patent listings published prior to August 18, 2003, only identify method-of-use claims. The listed patents may include drug substance and/or drug product claims that are not indicated in the listing.
• As of December 5, 2016, an NDA holder submitting information on a patent that claims both the drug substance and the drug product (and is eligible for listing on either basis) is required only to specify that it claims either the drug substance or the drug product. Orange Book users should not rely on an Orange Book patent listing, regardless of when first published, to determine the range of patent claims that may be asserted by an NDA holder or patent owner.

Patent and Exclusivity for: N208090

Product 005
OXYCODONE (XTAMPZA ER) CAPSULE, EXTENDED RELEASE 36MG

Patent Data

Product No	Patent No	Patent Expiration	Drug Substance	Drug Product	Patent Use Code	Delist Requested	Submission Date
005	7399488	03/24/2025		DP			07/19/2016
005	7771707	03/24/2025		DP			07/19/2016
005	8449909	03/24/2025		DP			07/19/2016
005	8557291	03/21/2025		DP			07/19/2016
005	8758813	06/10/2025			U-1556		07/19/2016
005	9682075	12/10/2030		DP	U-1556		06/20/2017
005	9737530	09/02/2036		DP	U-1556		08/23/2017
005	9968598	09/02/2036		DP	U-1556		05/16/2018
005	10004729	12/10/2030		DP	U-1556		07/10/2018
005	10188644	09/02/2036		DP	U-1556		01/29/2019
005	10646485	09/02/2036		DP	U-1556		05/13/2020
005	10668060	12/10/2030		DP	U-1556		06/03/2020

Exclusivity Data

Product No	Exclusivity Code	Exclusivity Expiration

 

 

View a list of all patent use codes
View a list of all exclusivity codes